New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 21, 2018 - The FDA announced the approval of Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz), for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Download PDF
Return to publications
